BUSINESS SEGMENT INFORMATION |
12.
BUSINESS SEGMENT INFORMATION
As referenced above in Note 1, the Company operates in three reportable segments: Logistics, Life Sciences and Manufacturing.
The Company’s Chief Executive Officer regularly reviews financial information at the reporting segment level in order to make decisions about resources to be allocated to the segments and to assess their performance.
The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the three and nine months ended June 30, 2025 (in thousands):
| | | | | | | | | | | | | | | | | | | | |
For the three months ended June 30, 2025 | |
| Consolidated | | |
| Logistics | | |
| Life Sciences | | |
| Manufacturing | | |
| Corporate | |
Revenues
| |
$ | 49,145 | | |
$ | 43,231 | | |
$ | 3,490 | | |
$ | 2,424 | | |
$ | — | |
Forwarding expenses and cost of revenues
| |
| 33,035 | | |
| 31,259 | | |
| 624 | | |
| 1,152 | | |
| — | |
Gross profit
| |
| 16,110 | | |
| 11,972 | | |
| 2,866 | | |
| 1,272 | | |
| — | |
Selling, general and administrative
| |
| 13,525 | | |
| 9,434 | | |
| 2,062 | | |
| 764 | | |
| 1,265 | |
Amortization of intangible assets
| |
| 654 | | |
| — | | |
| — | | |
| — | | |
| 654 | |
Income (loss) from operations
| |
| 1,931 | | |
| 2,538 | | |
| 804 | | |
| 508 | | |
| (1,919 | ) |
Interest expense
| |
| 442 | | |
| 289 | | |
| 73 | | |
| 80 | | |
| — | |
Identifiable assets
| |
| 126,032 | | |
| 52,255 | | |
| 13,349 | | |
| 4,453 | | |
| 55,975 | |
Capital expenditures, net of disposals
| |
| 69 | | |
| 5 | | |
| 45 | | |
| 19 | | |
| — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
For the nine months ended June 30, 2025
| |
|
Consolidated
| | |
|
Logistics
| | |
|
Life Sciences
| | |
|
Manufacturing
| | |
|
Corporate
| |
Revenues
| |
$ | 151,230 | | |
$ | 133,361 | | |
$ | 10,639 | | |
$ | 7,230 | | |
$ | — | |
Forwarding expenses and cost of revenues
| |
| 103,407 | | |
| 98,155 | | |
| 1,870 | | |
| 3,382 | | |
| — | |
Gross profit
| |
| 47,823 | | |
| 35,206 | | |
| 8,769 | | |
| 3,848 | | |
| — | |
Selling, general and administrative
| |
| 40,576 | | |
| 28,327 | | |
| 5,979 | | |
| 2,507 | | |
| 3,763 | |
Amortization of intangible assets
| |
| 1,937 | | |
| — | | |
| — | | |
| — | | |
| 1,937 | |
Income (loss) from operations
| |
| 5,310 | | |
| 6,879 | | |
| 2,790 | | |
| 1,341 | | |
| (5,700 | ) |
Interest expense
| |
| 1,668 | | |
| 1,168 | | |
| 280 | | |
| 220 | | |
| — | |
Identifiable assets
| |
| 126,032 | | |
| 52,255 | | |
| 13,349 | | |
| 4,453 | | |
| 55,975 | |
Capital expenditures, net of disposals | |
| 396 | | |
| 31 | | |
| 346 | | |
| 19 | | |
| — | |
The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the three and nine months ended June 30, 2024 (in thousands):
| | | | | | | | | | | | | | | | | | | | |
For the three months ended June 30, 2024
|
| |
Consolidated
| | |
|
Logistics
| | |
|
Life Sciences
| | |
|
Manufacturing
| | |
|
Corporate
| |
Revenues
|
| | 46,724 | | |
$ | 40,677 | | |
$ | 3,208 | | |
$ | 2,839 | | |
$ | — | |
Forwarding expenses and cost of revenues
|
| | 31,633 | | |
| 29,725 | | |
| 609 | | |
| 1,299 | | |
| — | |
Gross profit
|
| | 15,091 | | |
| 10,952 | | |
| 2,599 | | |
| 1,540 | | |
| — | |
Selling, general and administrative
|
| | 13,358 | | |
| 9,444 | | |
| 1,812 | | |
| 793 | | |
| 1,309 | |
Amortization of intangible assets
|
| | 555 | | |
| — | | |
| — | | |
| — | | |
| 555 | |
Income (loss) from operations
|
| | 1,178 | | |
| 1,508 | | |
| 787 | | |
| 747 | | |
| (1,864 | ) |
Interest expense
|
| | 589 | | |
| 426 | | |
| 97 | | |
| 66 | | |
| — | |
Identifiable assets
|
| | 108,566 | | |
| 42,025 | | |
| 12,075 | | |
| 4,374 | | |
| 50,092 | |
Capital expenditures, net of disposals
|
| | 331 | | |
| 21 | | |
| 302 | | |
| 8 | | |
| — | |
| | | | | | | | | | | | | | | | | | | | |
For the nine months ended June 30, 2024
| |
|
Consolidated
| | |
|
Logistics
| | |
|
Life Sciences
| | |
|
Manufacturing
| | |
|
Corporate
| |
Revenues
| |
$ | 129,881 | | |
$ | 111,991 | | |
$ | 10,213 | | |
$ | 7,677 | | |
$ | — | |
Forwarding expenses and cost of revenues
| |
| 86,822 | | |
| 81,232 | | |
| 2,065 | | |
| 3,525 | | |
| — | |
Gross profit
| |
| 43,059 | | |
| 30,759 | | |
| 8,148 | | |
| 4,152 | | |
| — | |
Selling, general and administrative
| |
| 38,664 | | |
| 27,186 | | |
| 5,307 | | |
| 2,364 | | |
| 3,807 | |
Amortization of intangible assets
| |
| 1,635 | | |
| — | | |
| — | | |
| — | | |
| 1,635 | |
Income (loss) from operations
| |
| 2,760 | | |
| 3,573 | | |
| 2,841 | | |
| 1,788 | | |
| (5,442 | ) |
Interest expense
| |
| 1,663 | | |
| 1,188 | | |
| 245 | | |
| 230 | | |
| — | |
Identifiable assets
| |
| 108,566 | | |
| 42,025 | | |
| 12,075 | | |
| 4,374 | | |
| 50,092 | |
Capital expenditures, net of disposals
| |
| 658 | | |
| 47 | | |
| 603 | | |
| 8 | | |
| — | |
|